Andere talen Eyenovia, Inc.

Aandelen

EYEN

US30234E1047

Geschatte realtime Cboe BZX Andere beurzen 18:48:19 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,684 ^USD	+17,22%		+31,96%	-66,32%

13:00	Eyenovia geeft klinische en wetenschappelijke updates over de door de FDA goedgekeurde producten Mydcombi en Clobetasol Propionate Ophthalmic Suspension	CI
08/04	Eyenovia onderzoekt potentiële verkoop en andere strategische alternatieven	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension	13:02
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension	13:00
Eyenovia to Weigh Potential Sale, Other Strategic Alternatives	08/04
Eyenovia Explores Wide Range of Strategic Alternatives	08/04
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities	08/04
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings	03/04
Eyenovia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update	18/03
North American Morning Briefing : Investors -2-	18/03
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023	15/03
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	13/03
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals	13/03
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th	11/03
Eyenovia Reports FDA Approval for Formosa's Post-Op Eye Inflammation, Pain Treatment	05/03
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery	05/03
US FDA approves Eyenovia's eye drug, Formosa Pharma says	05/03
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	13/02
Eyenovia, Inc Announces FDA Approval of Redwood City as Commercial Manufacturing Facility	13/02
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada	16/01
Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Eyenovia, Inc.

Aandelen

EYEN

US30234E1047

Andere talen

Filters